A study published online in the American Journal of Pharmaceutical Benefits on August 20, 2015 found that approximately 90% of adult cystic fibrosis patients surveyed preferred using a dry powder inhaler to using a standard nebulizer if the cost is the same. On average, the patients said that they would be willing to give up 5.3 years of life, out of an expected 40 … [Read more...] about Study finds that CF patients would give up 5+ years of their lives to use a DPI instead of a standard nebulizer
News
Advanced Inhalation Therapies files for IPO
Israeli biopharmaceutical company Advanced Inhalation Therapies (AIT), which recently received orphan drug status in Europe for its inhaled nitric oxide for the treatment of cystic fibrosis, has filed with the US Securities and Exchange Commission (SEC) for an initial public offering. The company is looking to raise up to $36 million to support Phase 2 development of … [Read more...] about Advanced Inhalation Therapies files for IPO
Skyepharma reports revenues from flutiform have risen significantly
Skyepharma has reported that in-market sales of the flutiform fluticasone/formoterol MDI for the first 6 months of 2015 have totaled €65.1 million, up from €28.4 million in the first half of 2014, and the directors now predict that flutiform revenues will exceed previous expectations for the year. Skyepharma CEO Peter Grant commented, ""With a strong start to the … [Read more...] about Skyepharma reports revenues from flutiform have risen significantly
Raptor Pharmaceutical acquires Quinsair levofloxacin inhalation solution
Raptor Pharmaceutical Co. plans to launch Quinsair inhaled levofloxacin inhalation solution in Europe and Canada by mid-2016, the company said after announcing that it has agreed to pay Tripex Pharmaceuticals $68.4 million upfront and up to $350 million in milestone payments and royalties to acquire global rights to the product. Quinsair (formerly Aeroquin) was … [Read more...] about Raptor Pharmaceutical acquires Quinsair levofloxacin inhalation solution
Phase 3 data show Stiolto/Spiolto Respimat improves quality of life
Boehringer Ingelheim has published new data from the two OTEMTO Phase 3b trials of the Stiolto/Spiolto Respimat tiotropium/olodaterol SMI for the treatment of COPD. The data show that the inhaler produced clinically meaningful improvements in quality of life versus placebo as measured by the St. George's Respiratory Questionnaire (SRGQ). The soft mist inhaler is … [Read more...] about Phase 3 data show Stiolto/Spiolto Respimat improves quality of life
Cirrus Pharmaceuticals hires Andrew Hamer as VP R&D
Cirrus Pharmaceuticals announced that it has hired Andrew Hamer as VP R&D. Hamer was most recently Senior Director of R&D Operations at GSK's dermatology subsidiary Stiefel. He also has experience in OINDP development at Cardinal, Sanofi, and Covance. Cirrus, based in Research Triangle Park, NC, was acquired by Kemwell in 2013. It offers inhalation and nasal … [Read more...] about Cirrus Pharmaceuticals hires Andrew Hamer as VP R&D
MannKind appoints Raymond Urbanski as Chief Medical Officer
MannKind Corporation has announced the appointment of former Mylan CMO Raymond Urbanski as its Chief Medical Officer. Urbanski has also held positions at Metabolix, Pfizer, and Suntory, with experience in drug development for oncology, rheumatology, cardiology, endocrinology, and immunology. MannKind CEO Hakan Edstrom commented, "Dr. Urbanski is a terrific addition … [Read more...] about MannKind appoints Raymond Urbanski as Chief Medical Officer
Pulmatrix announces plans for Phase 1 trial of inhaled anti-fungal for CF, BE study for LAMA
According to an update from Pulmatrix, the company has enough capital to fund development of its inhaled drug portfolio through the middle of 2017, and its plans over the next year and a half include the initiation of a Phase 1 trial of PUR1900 for the treatment of cystic fibrosis, and a pharmacokinetic bioequivalence study of PUR0200 for the treatment of COPD. … [Read more...] about Pulmatrix announces plans for Phase 1 trial of inhaled anti-fungal for CF, BE study for LAMA
Novartis launches Sequadra indacaterol/glycopyrronium inhaler in India
Novartis Healthcare Private Limited has announced the launch of the Sequadra indacaterol/glycopyrronium (110mcg/50mcg) DPI for the treatment of COPD in India. Novartis's indacaterol/glycopyrronium DPI is marketed in Europe and Japan as Ultibro Breezhaler. Novartis filed an NDA for the inhaler with the FDA in late 2014. Novartis India Country President Jawed Zia … [Read more...] about Novartis launches Sequadra indacaterol/glycopyrronium inhaler in India
Cipla announces the upcoming launch of the Synchrobreathe inhaler
Cipla has announced that it will launch the Synchrobreathe breath-actuated inhaler, which the company says requires low inspiratory flow to actuate, by the end of 2015. Company executives discussed the new inhaler at the 2015 South Africa Thoracic Society Conference. Cipla Global Head of Respiratory Frank Pieters commented, “Simple and intuitive, Synchrobreathe is … [Read more...] about Cipla announces the upcoming launch of the Synchrobreathe inhaler